Contact
Please use this form to send email to PR contact of this press release:
Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics’ Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers
TO: